272 related articles for article (PubMed ID: 32145263)
1. Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
Gelosa P; Castiglioni L; Camera M; Sironi L
Biochem Pharmacol; 2020 Jul; 177():113895. PubMed ID: 32145263
[TBL] [Abstract][Full Text] [Related]
2. Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing.
Regulska K; Regulski M; Karolak B; Murias M; Stanisz B
Drug Discov Today; 2019 Apr; 24(4):1059-1065. PubMed ID: 30878563
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.
Benjamin DJ; Haslam A; Prasad V
Cancer Med; 2024 Mar; 13(5):e7049. PubMed ID: 38491813
[TBL] [Abstract][Full Text] [Related]
4. Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs.
Regulska K; Regulski M; Karolak B; Michalak M; Murias M; Stanisz B
Pharmacol Res; 2019 Sep; 147():104326. PubMed ID: 31340189
[TBL] [Abstract][Full Text] [Related]
5. Common cardiovascular medications in cancer therapeutics.
Vaklavas C; Chatzizisis YS; Tsimberidou AM
Pharmacol Ther; 2011 May; 130(2):177-90. PubMed ID: 21277894
[TBL] [Abstract][Full Text] [Related]
6. Repurposing of approved cardiovascular drugs.
Ishida J; Konishi M; Ebner N; Springer J
J Transl Med; 2016 Sep; 14():269. PubMed ID: 27646033
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home.
Joseph J; Koka M; Aronow WS
J Am Med Dir Assoc; 2008 Feb; 9(2):124-7. PubMed ID: 18261706
[TBL] [Abstract][Full Text] [Related]
8. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
Lee HY; Cooke CE; Robertson TA
J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
Thakur V; Rankin KN; Hartling L; Mackie AS
Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
[TBL] [Abstract][Full Text] [Related]
11. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
[TBL] [Abstract][Full Text] [Related]
12. Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
Guirguis-Blake J
Am Fam Physician; 2012 Jul; 86(1):21-3. PubMed ID: 22962909
[No Abstract] [Full Text] [Related]
13. Treatment of Cardiovascular Diseases Among Elderly Residents of Long-term Care Facilities.
Kańtoch A; Gryglewska B; Wójkowska-Mach J; Heczko P; Grodzicki T
J Am Med Dir Assoc; 2018 May; 19(5):428-432. PubMed ID: 29402648
[TBL] [Abstract][Full Text] [Related]
14. Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
Lonn E; Grewal J
Curr Vasc Pharmacol; 2006 Jul; 4(3):253-68. PubMed ID: 16842143
[TBL] [Abstract][Full Text] [Related]
15. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
16. Under-prescribing of cardiovascular therapies for diabetes in primary care.
Bennett KE; Williams D; Feely J
Eur J Clin Pharmacol; 2003 Apr; 58(12):835-41. PubMed ID: 12698311
[TBL] [Abstract][Full Text] [Related]
17. Optimizing prevention and guideline-concordant care in Montenegro.
Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
[TBL] [Abstract][Full Text] [Related]
18. Use of cardiovascular drugs after acute myocardial infarction: a marked shift towards evidence-based drug therapy.
Reikvam A; Kvan E; Aursnes I
Cardiovasc Drugs Ther; 2002 Sep; 16(5):451-6. PubMed ID: 12652115
[TBL] [Abstract][Full Text] [Related]
19. Associations between Pharmacotherapy for Cardiovascular Diseases and Periodontitis.
Pająk-Łysek E; Polak M; Kopeć G; Podolec M; Desvarieux M; Pająk A; Zarzecka J
Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33477530
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
Liu Y; Ma X; Zheng J; Jia J; Yan T
BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
